Company news
Bioxcel Therapeutics, Inc. (NASDAQ:BTAI) news
Bioxcel Therapeutics, Inc. news releases on 6ix. Latest, May 28, 2026: BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial…
Press releases & updates
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
May 28, 2026
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 15, 2026
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
April 17, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
April 7, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
March 31, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting
March 30, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
March 26, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
March 10, 2026
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
March 9, 2026
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
March 4, 2026
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
February 18, 2026
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
February 12, 2026
Rigel Appoints Michael P. Miller to the Board of Directors
February 3, 2026
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
January 20, 2026
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
January 12, 2026
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
January 7, 2026
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
December 3, 2025
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
November 12, 2025
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
October 14, 2025
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
October 13, 2025
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
September 18, 2025
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
September 10, 2025
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
August 27, 2025
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
August 26, 2025
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
August 19, 2025
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
August 18, 2025
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
August 13, 2025
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
August 12, 2025
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference
August 11, 2025
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
August 6, 2025
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
August 1, 2025
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
July 21, 2025
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
July 1, 2025
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
May 27, 2025
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
May 27, 2025
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
March 27, 2025
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
March 11, 2025
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
March 7, 2025
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
March 4, 2025
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
March 3, 2025
BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia
March 3, 2025
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
February 28, 2025
BioXcel Therapeutics Announces Reverse Stock Split
February 5, 2025
BioXcel Therapeutics Provides Clinical and Business Update
February 4, 2025
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
November 21, 2024
BioXcel Therapeutics Announces Proposed Public Offering
November 20, 2024
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
November 13, 2024
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
November 11, 2024